David Berman Sells 5,965 Shares of Immunocore (NASDAQ:IMCR) Stock

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) insider David Berman sold 5,965 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $192,967.75. Following the sale, the insider owned 5,859 shares in the company, valued at $189,538.65. The trade was a 50.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Immunocore Stock Down 1.5%

IMCR stock opened at $32.68 on Friday. The firm has a 50 day moving average of $33.81 and a 200 day moving average of $34.30. The stock has a market capitalization of $1.65 billion, a PE ratio of -57.33 and a beta of 0.78. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99. Immunocore Holdings PLC Sponsored ADR has a 52 week low of $23.15 and a 52 week high of $40.71.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Leonteq Securities AG acquired a new position in Immunocore in the fourth quarter valued at approximately $30,000. GAMMA Investing LLC increased its holdings in shares of Immunocore by 51.6% during the 3rd quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock valued at $33,000 after purchasing an additional 311 shares in the last quarter. Harbour Investments Inc. lifted its stake in shares of Immunocore by 60.2% in the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after purchasing an additional 388 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in Immunocore by 4,696.3% during the second quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock worth $41,000 after buying an additional 1,268 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Immunocore during the second quarter valued at $42,000. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Key Immunocore News

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Analyst and institutional support: multiple brokers still carry buy/overweight views and the consensus average price target (~$60.90) sits well above the current market level, which can underpin upside if clinical or commercial progress resumes. MarketBeat IMCR Coverage
• Positive Sentiment: High institutional ownership (~84.5%): large, stable holders (Primecap, Bellevue, Tang Capital, Millennium, Armistice) can reduce free float and provide support over the medium term as long-term investors remain committed. MarketBeat IMCR Coverage
• Neutral Sentiment: Strong liquidity on the balance sheet: very high current and quick ratios (~6.0) reduce short-term solvency risk but are unlikely to drive near-term share moves absent new catalysts.
• Neutral Sentiment: Short-interest data appears inconsistent: the recent report shows effectively 0 shares short (and 0 days to cover), which is likely a reporting anomaly and should be treated cautiously rather than interpreted as a market signal.
• Neutral Sentiment: Lower-than-average intraday volume can amplify price moves on either positive or negative news; monitor volume for conviction on any follow-through.
• Negative Sentiment: Clustered insider selling: CEO Bahija Jallal sold 11,474 shares (~48% reduction in her stake) and several other senior insiders (David Berman, John Goll, Tina Leger) also sold large portions on the same day—a development that commonly pressures sentiment and can trigger short‑term selling. InsiderTrades: CEO Sells IMCR SEC Form 4 (Berman)

Wall Street Analysts Forecast Growth

A number of analysts have commented on IMCR shares. Morgan Stanley lifted their price target on Immunocore from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research report on Monday, November 10th. UBS Group set a $55.00 price objective on Immunocore and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of Immunocore in a report on Wednesday, February 4th. Finally, Wells Fargo & Company assumed coverage on shares of Immunocore in a research note on Friday, October 31st. They set an “overweight” rating and a $60.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Immunocore currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.90.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.